Skip to main content
Erschienen in: Journal of Infection and Chemotherapy 5/2013

01.10.2013 | Case Report

Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections

verfasst von: Emiko Ohki, Yuka Yamagishi, Hiroshige Mikamo

Erschienen in: Journal of Infection and Chemotherapy | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

The efficacy of fluoroquinolones (FQs) correlates with the pharmacokinetic/pharmacodynamic (PK–PD) parameter, AUC/MIC. To our knowledge, however, no prospective studies have reported the relationship between FQ efficacy and PK–PD parameters in intraabdominal infection; therefore, we prospectively investigated the relationship between the efficacy of intravenous ciprofloxacin (CPFX IV) and PK–PD parameters. The study included 16 patients diagnosed with peritonitis between 2006 and 2008: 14 patients infected with a single organism and 2 patients infected with more than one organism. Each patient was treated with CPFX IV (300 mg twice daily). The response rate was 56 % (9 responders and 7 non-responders). Non-responders were infected with Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis (6 patients were infected with a single organism and 1 with more than one organism). Plasma drug concentrations were measured 1 h and 2 or 4 h after administration of CPFX IV. AUC for 24 h (AUC0–24)/MIC values was calculated. The range of AUC0–24/MIC values in responders [95.3–3628.4 (geometric mean, 521.6)] was significantly different from that in non-responders [7.0–45.2 (geometric mean, 16.5)] (p = 0.001). The target AUC/MIC value of CPFX IV would be considered to be 45–95 in patients with peritonitis.
Literatur
1.
Zurück zum Zitat Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073–81.PubMedCrossRef Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073–81.PubMedCrossRef
2.
Zurück zum Zitat Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharamacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279:125–9.PubMedCrossRef Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharamacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279:125–9.PubMedCrossRef
3.
Zurück zum Zitat Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7:589–96.PubMedCrossRef Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7:589–96.PubMedCrossRef
4.
Zurück zum Zitat Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997;40(suppl A):45–57. Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997;40(suppl A):45–57.
5.
Zurück zum Zitat Craig WA. The role of pharmacodynamics in effective treatment of community-acquired pathogens. Adv Stud Med. 2002;2:126–34. Craig WA. The role of pharmacodynamics in effective treatment of community-acquired pathogens. Adv Stud Med. 2002;2:126–34.
6.
Zurück zum Zitat Matsuo K, Azuma M, Kasai M, Hanji I, Kimura I, Kosugi T, et al. Investigation of the clinical efficacy and dosage of intravenous ciprofloxacin in patients with respiratory infection. J Pharm Pharm Sci. 2008;11(2):111s–7s. Matsuo K, Azuma M, Kasai M, Hanji I, Kimura I, Kosugi T, et al. Investigation of the clinical efficacy and dosage of intravenous ciprofloxacin in patients with respiratory infection. J Pharm Pharm Sci. 2008;11(2):111s–7s.
7.
Zurück zum Zitat Saito A, Inamatsu T, Okada J, Oguri T, Kanno H, Kumon H, et al. Report from the committee on antimicrobial susceptibility testing, Japanese Society of Chemotherapy (1992). Chemotherapy. 1993;41:183–9. Saito A, Inamatsu T, Okada J, Oguri T, Kanno H, Kumon H, et al. Report from the committee on antimicrobial susceptibility testing, Japanese Society of Chemotherapy (1992). Chemotherapy. 1993;41:183–9.
8.
Zurück zum Zitat Ashihara Y, Yuki S, Kobayashi N, Asada Y. Studies on bioassay method of Bay o 9867 (ciprofloxacin) concentrations in body fluid. Chemotherapy. 1985;33:76–80. Ashihara Y, Yuki S, Kobayashi N, Asada Y. Studies on bioassay method of Bay o 9867 (ciprofloxacin) concentrations in body fluid. Chemotherapy. 1985;33:76–80.
9.
Zurück zum Zitat Beal SL, Sheiner LB. NONMEM users guides. University of San Francisco, San Francisco: NONMEM Project Group UCSF; 1992. Beal SL, Sheiner LB. NONMEM users guides. University of San Francisco, San Francisco: NONMEM Project Group UCSF; 1992.
10.
Zurück zum Zitat Azuma J, Yamamoto I, Seto Y, Maruyama K, Yoshikawa Y, Okumura K, et al. Ciprofloxacin i.v. (BAY q 3939) pharmacokinetic study.—Multiple administration of ciprofloxacin 300 mg by 60 min. intravenous drip infusion in healthy volunteers. Clin Rep. 1997;31:2701–25. Azuma J, Yamamoto I, Seto Y, Maruyama K, Yoshikawa Y, Okumura K, et al. Ciprofloxacin i.v. (BAY q 3939) pharmacokinetic study.—Multiple administration of ciprofloxacin 300 mg by 60 min. intravenous drip infusion in healthy volunteers. Clin Rep. 1997;31:2701–25.
11.
Zurück zum Zitat Aikawa N, Sasaki J, Iwai S, Kunimatsu M, Furuhata H, Watanabe T, et al. Clinical investigation of intravenous ciprofloxacin in severe and/or refractor infections in the surgical and gynecological fields. Jpn J Chemother. 1997;45:936–50. Aikawa N, Sasaki J, Iwai S, Kunimatsu M, Furuhata H, Watanabe T, et al. Clinical investigation of intravenous ciprofloxacin in severe and/or refractor infections in the surgical and gynecological fields. Jpn J Chemother. 1997;45:936–50.
12.
Zurück zum Zitat Yamaguchi K, Murakami M, Takahashi A, Ishii Y, Iwata M, Itoh K, et al. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. Jpn J Antibiot. 2005;58:655–89.PubMed Yamaguchi K, Murakami M, Takahashi A, Ishii Y, Iwata M, Itoh K, et al. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. Jpn J Antibiot. 2005;58:655–89.PubMed
13.
Zurück zum Zitat Yamaguchi K, Ishii Y, Yamanaka K, Watanabe N, Uehara N, Kaku M, et al. Nationwide susceptibility surveillance of ciprofloxacin and various parenteral antimicrobials against bacteria isolated from patients with severe infections–third ciproxan injection special survey (2005). Jpn J Antibiot. 2008;61:241–68.PubMedCrossRef Yamaguchi K, Ishii Y, Yamanaka K, Watanabe N, Uehara N, Kaku M, et al. Nationwide susceptibility surveillance of ciprofloxacin and various parenteral antimicrobials against bacteria isolated from patients with severe infections–third ciproxan injection special survey (2005). Jpn J Antibiot. 2008;61:241–68.PubMedCrossRef
14.
Zurück zum Zitat Mikamo H, Ninomiya M, Tamaya T. Pharmacokinetics of single-dose intravenous ciprofloxacin in blood and ascites of patients with pelvic peritonitis. J Infect Chemother. 2003;9:276–7.PubMedCrossRef Mikamo H, Ninomiya M, Tamaya T. Pharmacokinetics of single-dose intravenous ciprofloxacin in blood and ascites of patients with pelvic peritonitis. J Infect Chemother. 2003;9:276–7.PubMedCrossRef
15.
Zurück zum Zitat Mikamo H, Tanaka K, Watanabe K. Strategic use of antimicrobial agents. Antibiotic cycling and antibiotic mixing. Prog Med. 2005;25:2323–8. Mikamo H, Tanaka K, Watanabe K. Strategic use of antimicrobial agents. Antibiotic cycling and antibiotic mixing. Prog Med. 2005;25:2323–8.
16.
Zurück zum Zitat Mikamo H, Tamaya T, Ito K, Izumi K, Tanaka K, Watanabe K. Effectiveness of switch therapy for peritonitis. Jpn J Antibiot. 2007;60:200–5.PubMed Mikamo H, Tamaya T, Ito K, Izumi K, Tanaka K, Watanabe K. Effectiveness of switch therapy for peritonitis. Jpn J Antibiot. 2007;60:200–5.PubMed
Metadaten
Titel
Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections
verfasst von
Emiko Ohki
Yuka Yamagishi
Hiroshige Mikamo
Publikationsdatum
01.10.2013
Verlag
Springer Japan
Erschienen in
Journal of Infection and Chemotherapy / Ausgabe 5/2013
Print ISSN: 1341-321X
Elektronische ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-012-0512-6

Weitere Artikel der Ausgabe 5/2013

Journal of Infection and Chemotherapy 5/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.